NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.
The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases.
The Colorado State University Regional Biocontainment Laboratory is one of the NIAID-supported Regional Biocontainment Laboratories. The Center provides a safe, secure, state of art facility for university investigators, government scientists and industry representatives to collaboratively research bacteria and viruses that cause human and animal diseases
George Mason University's Biomedical Research Laboratory (BRL) is one of the NIAID supported Regional Biocontainment Laboratories. It operates as a central core facility in the Institute for Biohealth Innovation to advance research and develop novel diagnostics, therapeutics, and vaccines against viral and bacterial infectious agents by a diverse population of investigators.
The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.
The Tufts New England Regional Biosafety Laboratory (RBL) is one of the NIAID-supported Regional Biocontainment Laboratories. The RBL is a 41,000 square foot resource available to researchers in industry, academia, government and not-for-profit, dedicated to the study of existing and emerging infectious diseases, toxin-mediated diseases and medical countermeasures important to biodefense.
The Tulane University Regional Biosafety Laboratory (RBL) at The Tulane National Primate Research Center is one of the NIAID-supported Biocontainment Laboratories.
The regional biocontainment laboratory at University of Alabama at Birmingham (UAB), called Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB), is one of the NIAID-supported Biocontainment Laboratories. The Lab houses state-of-the art biosafety level 2 and level 3 laboratories as well as animal biosafety level 3 laboratories.
The University of Chicago Howard T. Ricketts Laboratory (HTRL) is one of the NIAID-supported Biocontainment Laboratories. The HTRL is a state of the art BSL-3 facility constructed to support research on bacterial and viral pathogens.
The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories. The Lab provides a valuable national resource and asset to the University of Louisville, our region, and the greater scientific and public health communities. The Lab has been built to the most stringent federal standards
The University of Missouri Laboratory for Infectious Disease Research (LIDR) is one of the NIAID-supported Biocontainment Laboratories.
The University of Pittsburgh Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories.
The University of Tennessee Regional Biocontainment Laboratory (RBL) is one of the NIAID-supported Biocontainment Laboratories. The RBL provides a secure lab for conducting research on Category A and B infectious pathogens using state-of-the-art molecular pathogenesis and immunologic approaches.
As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms underlying the spread of infectious diseases and the pathogenesis of the diseases they cause.
The NIAID-funded Bioinformatics Resource Centers provide data-driven, production-level, sustainable computational platforms to enable sharing and access to data, portable computational tools, and standards that support interoperability for the infectious diseases research community.
The Chicago Center for Functional Annotation (CCFA) is defining gene function on multiple scales, using a multi-disciplinary set of cellular, genetic, molecular, and biochemical approaches. The primary goal of the CCFA is to define the biochemical and cellular functions of uncharacterized genes in the NIAID priority pathogens, Yersinia pestis and Brucella abortus.
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical specimens.
The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.
Note: Devices are excluded.
Part of the Therapeutic Development Services program.
The Orfeome Project is part of the NIAID-supported Functional Genomics Program. The project is a collaboration of immunolgy and RNA/DNA virus pathogenesis experts, working together to address the hypothesis that RNA and DNA viruses encode common and unique mechanisms to manipulate virus replication efficiency and host responses to determine severe disease outcomes.
The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclonal antibodies, against viral (other than HIV), bacterial, parasitic, and fungal pathogens, includin
This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.
NIAID-funded researchers at ATCC and Tufts University have developed SOPs for creating continuous in vitro culture systems for the intestinal parasite Cryptosporidium.
The Systems Biology Consortium for Infectious Diseases is a community of systems biologists who integrate experimental biology, computational tools and modeling across temporal and spatial scales to improve our understanding of infectious diseases.
The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.